Passage BIO, Inc. (PASG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Passage BIO, Inc., a Delaware corporation and emerging growth company, on September 18, 2025. The report covers events occurring on September 16, 2025, regarding changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Saqib Islam resigned from the Board of Directors and the Audit Committee effective immediately on September 16, 2025.
- Reason for Departure: The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Board Composition: The Board size was reduced from eight to seven members.
- Appointment: Athena Countouriotis, M.D., was appointed to the Audit Committee to fill the vacancy left by Mr. Islam.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, future outlook, or specific business risks. The only contingency noted is the immediate vacancy on the Audit Committee, which was addressed by the appointment of Dr. Countouriotis.
Key Facts for Investor Verification
- Confirm the effective date of Saqib Islam's resignation (September 16, 2025).
- Verify the appointment of Athena Countouriotis, M.D., to the Audit Committee.
- Note the reduction of the Board of Directors to seven members.
- Review subsequent filings for any financial updates, as this 8-K contains no financial metrics.